Edoardo Crimini

781 total citations
39 papers, 474 citations indexed

About

Edoardo Crimini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Edoardo Crimini has authored 39 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Edoardo Crimini's work include Cancer Genomics and Diagnostics (10 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (7 papers). Edoardo Crimini is often cited by papers focused on Cancer Genomics and Diagnostics (10 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (7 papers). Edoardo Crimini collaborates with scholars based in Italy, United States and Switzerland. Edoardo Crimini's co-authors include Giuseppe Curigliano, Chiara Corti, Carmen Criscitiello, Paolo Tarantino, Matteo Repetto, Carmen Belli, Dario Trapani, Elena Guerini‐Rocco, Luca Boscolo Bielo and Federica Giugliano and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Edoardo Crimini

36 papers receiving 469 citations

Peers

Edoardo Crimini

ONCOL

PRM

RNMI

Αngeliki Andrikopoulou Greece

Guilherme Nader Marta Belgium

Konstantinos Koutsoukos Greece

B. Tiangco Philippines

Benedetta Conte Italy

Krisztina Bogos Hungary

Kwan Chee Allen Chan Hong Kong

Eudald Felip Spain

Hélio Humberto Angotti Carrara Brazil

Kyrillus S. Shohdy Egypt

Αngeliki Andrikopoulou Greece

Edoardo Crimini

220 ×0.8

ONCOL

78 ×0.5

158 ×1.2

89 ×0.8

PRM

33 ×0.4

RNMI

Citations per year, relative to Edoardo Crimini Edoardo Crimini (= 1×) peers Αngeliki Andrikopoulou

Countries citing papers authored by Edoardo Crimini

Since Specialization

Citations

This map shows the geographic impact of Edoardo Crimini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edoardo Crimini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edoardo Crimini more than expected).

Fields of papers citing papers by Edoardo Crimini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edoardo Crimini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edoardo Crimini. The network helps show where Edoardo Crimini may publish in the future.

Co-authorship network of co-authors of Edoardo Crimini

This figure shows the co-authorship network connecting the top 25 collaborators of Edoardo Crimini. A scholar is included among the top collaborators of Edoardo Crimini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edoardo Crimini. Edoardo Crimini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Botticelli, Andrea, Simone Scagnoli, Valentina Guarneri, et al.. (2025). 15P The ROME trial: Personalized target therapy and immunotherapy in the breast cancer subgroup. ESMO Open. 10. 104569–104569. 1 indexed citations

Crimini, Edoardo, et al.. (2025). 14P Comprehensive genomic profiling to guide personalized targeted and immunotherapy in gastrointestinal tumors: Subgroup analysis of the ROME trial. Annals of Oncology. 36. S10–S11. 1 indexed citations

Belli, Carmen, Luca Boscolo Bielo, Matteo Repetto, et al.. (2024). Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers. The Oncologist. 29(8). 707–715. 2 indexed citations

Bielo, Luca Boscolo, Matteo Repetto, Edoardo Crimini, et al.. (2024). Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis. The Oncologist. 29(7). 560–565. 2 indexed citations

Crimini, Edoardo & Giuseppe Curigliano. (2024). Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate. Expert Opinion on Investigational Drugs. 33(8). 851–865. 7 indexed citations

Valenza, Carmine, Dario Trapani, Edoardo Crimini, et al.. (2024). Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study. ESMO Open. 9(8). 103662–103662.

Bielo, Luca Boscolo, Dario Trapani, Paola Zagami, et al.. (2024). Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations. ESMO Open. 9(10). 103731–103731. 3 indexed citations

Crimini, Edoardo, Luca Boscolo Bielo, Gabriele Antonarelli, et al.. (2024). Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting. Cancers. 16(2). 281–281. 6 indexed citations

Bielo, Luca Boscolo, Dario Trapani, Matteo Repetto, et al.. (2023). Variant allele frequency: a decision-making tool in precision oncology?. Trends in cancer. 9(12). 1058–1068. 35 indexed citations

10.

Ascione, Liliana, Edoardo Crimini, Dario Trapani, et al.. (2023). Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability. The Oncologist. 28(11). 944–960. 18 indexed citations

11.

Repetto, Matteo, Edoardo Crimini, Carmen Belli, et al.. (2023). A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data. European Journal of Cancer. 190. 112958–112958.

12.

Trapani, Dario, Edoardo Crimini, José Luís Sandoval, & Giuseppe Curigliano. (2023). Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?. Cancer treatment and research. 188. 343–351. 1 indexed citations

13.

Spitaleri, Gianluca, Pamela Trillo Aliaga, Ilaria Attili, et al.. (2023). Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?. Current Oncology. 30(5). 5072–5092. 9 indexed citations

14.

Morganti, Stefania, Antonio Marra, Edoardo Crimini, et al.. (2022). Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. Breast Cancer Research and Treatment. 192(3). 465–484. 9 indexed citations

15.

Aliaga, Pamela Trillo, Dario Trapani, José Luís Sandoval, et al.. (2021). Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. Cancers. 13(22). 5829–5829. 10 indexed citations

16.

Giugliano, Federica, Edoardo Crimini, Paolo Tarantino, et al.. (2021). First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. Cancer Treatment Reviews. 99. 102253–102253. 24 indexed citations

17.

Crimini, Edoardo, Matteo Repetto, Philippe Aftimos, et al.. (2021). Precision medicine in breast cancer: From clinical trials to clinical practice. Cancer Treatment Reviews. 98. 102223–102223. 39 indexed citations

18.

Corti, Chiara, Edoardo Crimini, Paolo Tarantino, et al.. (2021). SARS-CoV-2 vaccines for cancer patients: a call to action. European Journal of Cancer. 148. 316–327. 45 indexed citations

19.

Trapani, Dario, Sara Gandini, Chiara Corti, et al.. (2021). Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. Cancer Treatment Reviews. 97. 102205–102205. 19 indexed citations

20.

Tarantino, Paolo, et al.. (2020). Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opinion on Biological Therapy. 21(2). 127–133. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact